SG
LPCN icon

Societe Generale’s Lipocine LPCN Stock Holding History

Societe Generale’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$55K Buy
+1,068
New +$165K ﹤0.01% 2448

Other funds holding LPCN

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Societe Generale's LPCN Position: Q2 2016 in Review

Societe Generale opened a new position in Lipocine (LPCN) in Q2 2016: 1,068 shares worth $55K. The stake represents ﹤0.01% of the portfolio and ranks #2448 among its holdings.

54 funds tracked by Wall St. Rank hold LPCN as of Q2 2016.

  • Societe Generale held 1,068 shares of Lipocine worth $55K as of Q2 2016.
  • Lipocine was a new Societe Generale position in Q2 2016.
  • Lipocine made up ﹤0.01% of Societe Generale's portfolio in Q2 2016, its #2448 holding.
  • 54 funds tracked by Wall St. Rank held Lipocine as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.